

Rabbit anti-Human ARID1A/BAF250a Monoclonal Antibody | anti-ARID1A antibody

ARID1A/BAF250a (EP303)

CATALOG # AAA59392	HOST Rabbit	REACTIVITY Human
------------------------------	-----------------------	----------------------------


PRODUCT SYNONYMS

ARID1A/BAF250a; Monoclonal Antibody; ARID1A/BAF250a (EP303); arid1a; anti-arid1a; arid; anti-arid; anti ARID1A; anti-BAF250A; anti BAF250A; ARID domain containing protein 1A; AT rich interactive domain 1A SWI like; AT rich interactive domain containing protein 1A; B120; BAF250; BM029; brain protein 120; BRG1 associated factor 250; BRG1 associated factor 250a; C1orf4; chromatin remodeling factor p250; hELD; hOSA1; Osa homolog 1; OSA1 nuclear protein; P270; SMARCF1; SWI like protein; SWI SNF complex protein p270; ELD; MRD14; OSA1; anti-ARID1A antibody

PRODUCT SPECIFICATIONS

Host	Rabbit
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG
Clone Number	EP303
Form/Format	Paraffin, Frozen ARID1A is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
Immunogen	A synthetic peptide corresponding to residues of human ARID1A (BAF250a) protein.
Control	Breast, Fallopian Tube, Prostate, Testis, Transitional Cell Carcinoma, T Cell Lymphoblastic Lymphoma
Localization	Nuclear
Preparation and Storage	Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)

IMAGES



IHC (Immunohistochemistry)

ARID1A Antibody Immunohistochemistry on an FFPE Ovarian Serous Carcinoma Tissue

Antibody Type	Dilution	Volume/QTY
Prediluted	Ready-To-Use	3.0 ml
Prediluted	Ready-To-Use	7.0 ml
Prediluted	Ready-To-Use	15.0 ml
Concentrated	1:25-1:100	0.1 ml
Concentrated	1:25-1:100	0.5 ml
Concentrated	1:25-1:100	1.0 ml
Control Slides		5

Dilution Info

ADDITIONAL INFORMATION

Related Product Information for anti-ARID1A antibody	Genes encoding subunits of SWItch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexes are collectively mutated in 20% of all human cancers. ARID1A is the SWI/SNF subunit gene that is most frequently mutated, at variable frequencies across molecular and histological subtypes of cancer. ARID1A is a tumour suppressor gene frequently mutated in Clear Cell and Endometrioid Carcinomas of the Ovary and Endometrium. Loss of ARID1A function as shown by loss of expression, presumably due to mutations, is an early molecular event, occurring before malignant transformation, in the development of the majority of Ovarian Clear Cell and Endometrioid Carcinomas arising in Endometriomas. A study found 21 ARID1A antibody mutations were identified in 14/43 assessable tumours (33%), the majority of which were predicted to be deleterious. Mutations were identified in 6/17 (35%) Ovarian Clear Cell Carcinomas, 5/8 (63%) Ovarian Endometrioid Carcinomas, 2/5 (40%) Endometrial Carcinomas, and 1/7 (14%) Carcinosarcomas. Some studies have demonstrated that ARID1A has a critical tumor suppressor role in the Colon, and that its inactivation leads to the development of Colon Cancers via a mechanism that is distinct from previously established genetic models. ARID1A inactivating mutations are present at a high frequency in advanced endocrine-resistant ER+ Breast Cancer. ARID1A may play an important role in and serves as a valuable prognostic marker in Gastric Cancer.
--	---

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://stage.aaabiotech.com/monoclonal/arid1a-baf250a-antibody-clone-ep303-elisa/59392>